Ultragenyx Pharmaceutical Inc.

12 hours ago · globenewswire.com

Monte Carlo Automotive (MCA) Centenaire was the first road car with a carbon fibre monocoque chassis and is powered by a 5.2-litre V12 from the Lamborghini Countach 5000 QV | This example of Monaco's first supercar, created in partnership with Lamborghini, is the first of just five Centenaire models produced | Originally retained by the Lamborghini factory and displayed at Rétromobile 2007, the Centenaire is now eligible for many prestigious concours events | Offered for sale at Broad Arrow's Zoute Concours Auction on 9 October 2026 in collaboration with Zoute Grand Prix Car Week Monte Carlo Automotive (MCA) Centenaire was the first road car with a carbon fibre monocoque chassis and is powered by a 5.2-litre V12 from the Lamborghini Countach 5000 QV | This example of Monaco's first supercar, created in partnership with Lamborghini, is the first of just five Centenaire models produced | Originally retained by the Lamborghini factory and displayed at Rétromobile 2007, the Centenaire is now eligible for many prestigious concours events | Offered for sale at Broad Arrow's Zoute Concours Auction on 9 October 2026 in collaboration with Zoute Grand Prix Car Week

4 days ago · zacks.com

Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data.

4 days ago · zacks.com

Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

4 days ago · seekingalpha.com

Ultragenyx Pharmaceutical Inc. (RARE) Discusses FDA Approval of FAYUVI as First Treatment for Sanfilippo Syndrome Type A Transcript

5 days ago · globenewswire.com

FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A

5 days ago · reuters.com

The U.S ​Food ‌and Drug ​Administration ​said on Thursday ⁠it ​has ​approved Ultragenyx's gene ​therapy ​for the treatment ‌of ⁠a rare, fatal ​disease.

5 days ago · prnewswire.com

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE).

19 days ago · zacks.com

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?

19 days ago · zacks.com

Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question.

19 days ago · benzinga.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) stock is tumbling on Thursday after reporting late-stage clinical trial failures for its Angelman syndrome therapy, apazunersen, prompting the biopharmaceutical firm to review the program's future and plan significant corporate expense reductions.